Inotek Pharmaceuticals

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. The Company's most advanced product candidate, trabodenoson, is a highly selective adenosine mimetic and the first potential treatment for glaucoma of its kind. 

Trabodenoson has high lipid solubility which results in high ocular penetration, allowing it to reach target tissues with topical administration. In addition, it exhibits high tissue compatibility with the often sensitive tissues in the front of the eye which may reduce the risk of side effects.

Company Growth (employees)
Type
Public
HQ
Lexington, US
Founded
1996
Size (employees)
19 (est)+12%
Inotek Pharmaceuticals was founded in 1996 and is headquartered in Lexington, US

Inotek Pharmaceuticals Office Locations

Inotek Pharmaceuticals has an office in Lexington
Lexington, US (HQ)
33 Hayden Avenue

Inotek Pharmaceuticals Data and Metrics

Inotek Pharmaceuticals Financial Metrics

USD

Net income (Q1, 2017)

(10.7 m)

EBIT (Q1, 2017)

(10 m)

Market capitalization (18-Aug-2017)

18 m

Cash (31-Mar-2017)

25.3 m
Inotek Pharmaceuticals's current market capitalization is $18 m.
USDFY, 2015FY, 2016

R&D expense

(12.6 m)(32 m)

General and administrative expense

(7.8 m)(9.9 m)

Operating expense total

(20.4 m)(41.9 m)

EBIT

(20.4 m)(41.9 m)

Interest expense

(1.2 m)(1.4 m)

Interest income

89 k443 k

Net Income

(68 m)(42.9 m)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

(1.1 m)(2 m)(3.6 m)(7.6 m)(6.5 m)(8.4 m)(7.1 m)

General and administrative expense

(2 m)(1.7 m)(1.8 m)(2.5 m)(2.3 m)(2.3 m)(2.9 m)

Operating expense total

(3 m)(3.7 m)(5.4 m)(10.1 m)(8.8 m)(10.7 m)(10 m)

EBIT

(3 m)(3.7 m)(5.4 m)(10.1 m)(8.8 m)(10.7 m)(10 m)

Interest expense

(474 k)(564 k)(192 k)(474 k)(564 k)(525 k)(876 k)

Interest income

33 k69 k96 k120 k172 k

Net Income

(1.5 m)(2.8 m)(56 m)(10.1 m)(18.8 m)(29.9 m)(10.7 m)
USDFY, 2015FY, 2016

Cash

80 m29.8 m

Inventories

1.1 m1.9 m

Current Assets

112.4 m128.3 m

PP&E

812 k1.1 m

Total Assets

113.3 m129.6 m

Accounts Payable

1.6 m1.6 m

Current Liabilities

4.1 m7.2 m

Total Liabilities

56.5 m

Additional Paid-in Capital

304.6 m311.8 m

Retained Earnings

(196 m)(238.9 m)

Total Equity

108.8 m73.2 m

Financial Leverage

1 x1.8 x
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

53.1 m49 m89.2 m58.7 m38.5 m83 m25.3 m

Current Assets

53.4 m49.5 m119.2 m103.2 m98.7 m138.9 m116.6 m

PP&E

29 k756 k790 k976 k1 m1.1 m

Total Assets

55.5 m51.7 m120.1 m104.2 m99.9 m140.1 m117.9 m

Accounts Payable

1.3 m813 k1.7 m1.4 m921 k1.8 m1.9 m

Current Liabilities

2.5 m2.5 m3.2 m4.6 m4.1 m5.9 m5.3 m

Additional Paid-in Capital

163.3 m163.4 m304.1 m305.1 m309.9 m310.7 m312.6 m

Retained Earnings

(129.5 m)(131.9 m)(187.9 m)(206.1 m)(214.8 m)(225.9 m)(249.5 m)

Total Equity

34 m31.7 m116.5 m99.2 m95.4 m85.1 m63.3 m

Financial Leverage

1.6 x1.6 x1 x1.1 x1 x1.6 x1.9 x
USDFY, 2015FY, 2016

Net Income

(68 m)(42.9 m)

Depreciation and Amortization

45 k169 k

Accounts Payable

487 k(41 k)

Cash From Operating Activities

(17.4 m)(37.3 m)

Purchases of PP&E

(412 k)(487 k)

Cash From Investing Activities

(31.7 m)(66.1 m)

Short-term Borrowings

(5.8 m)(5.8 m)

Cash From Financing Activities

125.5 m53.1 m

Interest Paid

89 k89 k
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.5 m)(2.8 m)(56 m)(10.1 m)(18.8 m)(29.9 m)(10.7 m)

Depreciation and Amortization

6 k37 k72 k111 k61 k

Accounts Payable

154 k(333 k)563 k(257 k)(712 k)144 k310 k

Cash From Operating Activities

(2 m)(6.1 m)(10.4 m)(9 m)(17 m)(26.1 m)(11.6 m)

Purchases of PP&E

(30 k)(318 k)(15 k)(236 k)(344 k)(53 k)

Cash From Investing Activities

(30 k)(29.4 m)(12.3 m)(28.7 m)(23.8 m)7.1 m

Short-term Borrowings

(5.8 m)(5.8 m)(5.8 m)(5.8 m)(5.8 m)

Cash From Financing Activities

51.5 m51.5 m125.4 m51.5 m4.2 m52.9 m

Interest Paid

89 k89 k89 k89 k89 k89 k1.5 m
Y, 2017

Financial Leverage

1.9 x

Inotek Pharmaceuticals Operating Metrics

FY, 2016

Patent Portfolios

1

Phase III Trials

1

Inotek Pharmaceuticals Market Value History

Traffic Overview of Inotek Pharmaceuticals

Inotek Pharmaceuticals Company Life and Culture

You may also be interested in